Page 3 - Lance Liotta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eyes with lenses are believed to have evolved independently multiple times, but all evolutionary scenarios face insurmountable barriers.

Researchers test the therapeutic efficacy of potential COVID-19 interventions in mouse models Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. Related Stories For this study, the researchers are infecting ACE2 animals intranasally with SARS-CoV-2 and following them for up to seven days af...

 E-Mail Aarthi Narayanan, Associate Professor, and Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), are conducting three studies to assess the therapeutic efficacy of candidate interventions for COVID-19 in mouse models. For the first study, the researchers hope to determine the survival advantage conferred by a therapeutic. For this study, the researchers are infecting ACE2 animals intranasally with SARS-CoV-2 and following them for up to seven days after infection. As part of the second study, they are working to determine the survival advantage ...

 E-Mail IMAGE: Lance Liotta, MD, PhD, study PI, and George Mason University College of Science CAPMM co-founder and co-director. view more  Credit: Evan Cantwell, George Mason University A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army's Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments. George Mason University's College of Science announced an exciting $1.33 million collaboration with Rutgers Can...

Credit: Copyright: George Mason University 2021 Mason scientists employ a rapid-result, saliva-based test that significantly expands testing capacity, and an antibody test that can track vaccine response. George Mason University announces it is introducing a rapid-result, saliva-based COVID-19 test that will greatly expand testing capabilities on its campuses this spring. The effort, led by Mason's faculty, is part of a comprehensive program to better track and control the virus on campus. Mason scientists, who are pushing the boundaries of technologies that are keeping Mason's campuses safe...